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Abstract
Background: Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally
advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized
Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy
endpoint (pathological complete response).
We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at
3 and 5 years.
Methods: Patients (pts) were randomized to receive 5 weeks of radiotherapy (45 Gy/25 fractions) with concurrent
Capecitabine 825 mg/m2 twice daily, 5 days per week with (arm A) or without (arm b) bevacizumab (5 mg/kg once
every 2 weeks).
Results: In our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting
shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4
and 76.2% vs 78.2% at 3 and 5 years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5
years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%).
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Conclusions: the addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant
advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or
long term.
Trial registration: EudraCT number: 2009–010192-24.
Clinicaltrials.gov number: NCT01043484.
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Background
Significant progress in the management of locally
advanced rectal cancer (LARC) has been achieved during
the last two decades. This includes the use of postopera-
tive Radiotherapy [1]; postoperative chemoradiotherapy
(CRT) [2]; and the widespread implementation of total
mesorectal excision and autonomic nerve preservation
[3]. The German Rectal Cancer Study Group established
that there was a significant improvement in local con-
trol, toxicity profile and sphincter preservation in
patients with LARC treated with preoperative versus
postoperative CRT [4]. Currently perioperative CRT is
worldwide accepted as standard treatment in patients
with locally advanced (T3-T4) rectal cancer because it
improves local control and survival. This strategy
provides early exposure to systemic therapy, maximizes
downstaging, and increases the options of sphincter-
sparing surgery.
Although local recurrences with this approach have
dropped from 20 to 40% [5] to less than 10% with CRT
[6], the impact of 5FU added to radiotherapy in survival
has been questioned as systemic treatment following the
results of Bujko et al [7]. Probably a fluoropyrimidine-
alone chemotherapy regimen is unlikely to be adequate
as systemic treatment because its modest single-agent
activity in colorectal cancer might be compromised by
the reduced dosing necessary for safe concurrent admin-
istration with radiotherapy.
Capecitabine is a drug designed to improve the
convenience of 5FU and has largely replaced it in meta-
static and localized disease along with radiotherapy [8].
In the metastatic setting, bevacizumab (BVZ) increases
the activity of polychemotherapy [9] and fluoropyrimi-
dine monotherapy [10, 11] although its activity in com-
bination with FOLFOX in the first-line setting has been
questioned [12]. The advantage conferred by the treat-
ment with BVZ plus chemotherapy in the treatment of
CRC cancer patients could be due to increased tumour
cell sensitivity to the action of the chemotherapy, or the
better distribution of chemotherapy into the tumour. It
is an attractive drug to be used in combination with
fluoropyrimidines and radiation therapy given its good
tolerance, especially in a population whose average age
is over 65 years. Therefore, we published a randomized
phase II study in 2015 [13] and we present here its long
term results in survival outcomes.
Methods
Trial design
This study was a national, multicenter, open-label
randomized phase II trial performed by the Spanish
Cooperative Group for the Treatment of Digestive
Tumors (TTD Group). The study was performed follow-
ing the Declaration of Helsinki and Good Clinical Practice
Guidelines, and written informed consent was obtained
from all patients before taking part in the study. The
Reference Ethics Committee was Comité Ético de Investi-
gación Clínica del Hospital Universitario 12 de Octubre,
Avda de Córdoba, s/n, 28,041 Madrid. The protocol was
locally approved in all the participating centers by the in-
stitutional review boards. This study adhered to CON-
SORT guidelines and has strictly followed CONSORT
recommendations.
The main objective of the study was the complete
pathological response (ypCR) rate, defined as ypT0 and
ypN0 in the surgical specimen and was previously
reported as well as the possible molecular dynamic and
predictive factors of response in tissue of the diagnostic
tumoral biopsy and the angiogenic profile. Other
secondary objectives were: Disease-free survival (DFS)
and distant relapse-free survival (DRFS) at 3 and 5 years,
and overall survival (OS).
Disease-free survival (DFS) was defined as the time
elapsed between the randomization and the time of the
first local relapse; distant relapse-free survival (DRFS)
was defined as the time from randomization until the
moment of first distant relapse. OS was defined as the
time elapsed between randomization and date of death.
Once it was corroborated that patients had signed the
informed consent and fulfilled selection criteria, they
were randomly assigned in a 1:1 ratio to CRT treatment
with or without BVZ. Randomization was performed
centrally, by PIVOTAL Contract Research Organization.
Patient selection
Eligibility criteria included patients with clinical stages
II and III LARC within < 15 cm from the anal verge
(T and N defined by pelvic magnetic resonance
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imaging (MRI) and categorized according to the AJC
on Cancer Staging Manual 6th Edition), candidates to
surgical resection, with adequate organ and bone
marrow function, ECOG performance status 0 or 1,
age ≥ 18 years and chemotherapy and radiation therapy
naïve. Other patient’s selection criteria previously de-
scribed [13].
Treatment schedule
Patients were randomly assigned to radiotherapy (45Gy de-
livered in 25 daily fractions over 5weeks) with capecitabine
or capecitabine plus BVZ and stratified by center and
tumour location in upper, middle and lower rectum. Arm A
consisted of BVZ (5mg/kg) on day 1 of weeks 1, 3, and 5
plus capecitabine and patients included in arm B received
only capecitabine as previously described [13]. Patients
underwent surgery 6–8weeks after the completion of CRT
as part of clinical practice. The type of postoperative chemo-
therapy was not defined, nor if it should be used.
Capecitabine dose-modification criteria were estab-
lished but for bevacizumab no dose-reductions were
contemplated.
Evaluations during the study
A complete colonoscopy with biopsy, pelvic MRI, thora-
coabdominal computed tomography (or abdominal
Table 1 Post operatory toxicities
ARM A ARM B
Grade 3 (%) Grade 4 (%) Grade 3 (%) Grade 4 (%)
Abdominal abscess 2 (4.55) – – –
Peritonitis 2(4.55) – – –
Bacteremia 1(2.27) – – –
Perineal abscess – – 1(2.17) –
Septic shock – 1(2.27) – –
Tracheobronchitis 1(2.27) – – –
Urinary tract infection 1(2.27) – – –
Wound infection 1(2.27) – – –
Pelvic abscess – – 1(2.17) –
Post-operatory wound infection – – 1(2.17) –
Intestinal obstruction 2(4.55) – – –
Proctitis 1(2.27) – – –
Enterovesical fistula – – – 1(2.17)
Intestinal ischemia – – 1(2.17) –
Paralytic ileus – – 1(2.17) –
Anastomotic failure – 1(2.27) – 1(2.17)
Complication of a gastrointestinal stoma 1(2.27) – – ..
Wound dehiscence . 1(2.27) – –
Coagulopathy 1 (2.27) – – –
Anemia – – 1(2.17) –
Iron deficiency anemia – – 1(2.17) –
Auricular fibrillation 1 (2.27) – – –
Cardiorespiratory arrest . 1(2.27) – –
Acute renal injury 1 (2.27) – – –
Renal failure – – 1(2.17) –
Vaginal fistula – – 1(2.17) –
Hepatic insufficiency 1 (2.27) – – –
Chest pain 1 (2.27) – – –
Blood calcium 1 (2.27) – – –
Fistula – 1(2.27) – –
Hypertension – – 1(2.17) –
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computed plus tomography thoracic x-ray), and electro-
cardiogram were performed prior to the beginning of
the study. Laboratory studies (haematology, chemistry,
coagulation profile, urinalysis, carcinoembryonic anti-
gen) were repeated before the start of each treatment
cycle. Histologic assessment (ypT, ypN) and grading of
regression (according to Mandard scale) were assessed
after surgery. A follow-up of up to five years was
planned after surgery.
Sample size calculation and statistical analysis
The sample size and the decision rule were based on the
Simon, Wittes, and Ellenberg (SWE) method for ran-
domized phase II trials. Forty-one patients were needed
per arm assuming an ypCR proportion of 15% in one of
the arms, a difference between arms of 10%, and accept-
ing a probability of making a correct selection of 87%.
This number was increased by 10% until 90 considering
the possible loss of evaluable patients. All statistical tests
were two-sided. Additional data have been previously
published [13].
All eligible and consenting patients (the full analysis
population) were included in the analyses of OS, DRFS,
and DFS and the cumulative incidence rates of local
and distant recurrences, according to the intention-to-
treat principle.
Univariate analyses of survival were carried out by the
Kaplan–Meier method, and the evaluation of differences
was performed with the log-rank test.
Results
We previously published the baseline characteristics of
the patients participating in this study [13]; here we
present the long-term follow-up results at 3 and 5 years
of DFS, DRFS, and OS.
Ninety patients were included from December 2009
until March 2011 in 12 hospitals in Spain; 44 were
randomly assigned to arm A and 46 to arm B.
Patients received a median of 3 (range 2–3) BVZ
cycles, one dose delay of BVZ, there were no cases of
BVZ dose reductions or discontinuations. For both arms,
the median number of capecitabine received cycles was
Table 2 Tumoral regression among 89 resected patients
A (BVZ + CAPE + RT) (N = 44) B (CAPE + RT) (N = 46) Total (N = 90) P Value Test
Pathologic response per tumoral regression (TRG)*
TRG 1(Complete pathologic response) N(%) 8 (18.18) 5 (10.87) 13 (14.44) Fisher: 0.1458
TRG 2 N(%) 8 (18.18) 15 (32.61) 23 (25.56)
TRG 3 N(%) 14 (31.82) 19 (41.30) 33 (36.67)
TRG 4 N(%) 12 (27.27) 6 (13.04) 18 (20.00)
TRG 5(Disease progression) N(%) 0 (0.00) 1 (2.17) 1 (1.11)
ND N(%) 1 (2.27) 0 (0.00) 1 (1.11)
Missing N(%) 1 (2.27) 0 (0.00) 1 (1.11)
ypT improvement
Better N(%) 26 (59.09) 18 (39.13) 44 (48.89) Fisher: 0.0429
Remained the same N(%) 16 (36.36) 28 (60.87) 44 (48.89)
Worse N(%) 1 (2.27) 0 (0.00) 1 (1.11)
Missing N(%) 1 (2.27) 0 (0.00) 1 (1.11)
ypN improvement
Better N(%) 24 (54.55) 35 (76.09) 59 (65.56) Fisher: 0.0865
Remained the same N(%) 15 (34.09) 8 (17.39) 23 (25.56)
Worse N(%) 4 (9.09) 2 (4.35) 6 (6.67)
No evaluable* N(%) 0 (0.00) 1 (2.17) 1 (1.11)
Missing N(%) 1 (2.27) 0 (0.00) 1 (1.11)
ypT and ypN improvement
Improvement in both N(%) 18 (40.91) 16 (34.78) 34 (37.78) Fisher: 0.5612
Improvement in one N(%) 14 (31.82) 20 (43.48) 34 (37.78)
No improvement N(%) 11 (25.00) 9 (19.57) 20 (22.22)
Non-evaluable* N(%) 0 (0.00) 1 (2.17) 1 (1.11)
Missing N(%) 1 (2.27) 0 (0.00) 1 (1.11)
* A patient was reported as NX
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3 (range 1–3). There were not any statistically significant
differences regarding the number of patients with
delayed capecitabine cycles, occurring in 66.67% cycles
in arm A and 77.78 in arm B. Only 5 patients had early
treatment discontinuation (2 in arm A, 3 in arm B); 1
patient required a capecitabine dose reduction.
Overall, the median dose intensity was equivalent to
85% of expected, observing similar values across both
groups.
Safety, treatment-related toxicity and surgical outcomes
Treatment was well tolerated. Eighty patients (88.89%)
reported treatment-emergent adverse events. There were
no differences in grade 3–4 treatment-related toxicity.
No grade 3 or greater haematological toxicity was
reported. Two patients in arm A presented hypertension.
One patient in the study received only 2 cycles of BVZ
due to capecitabine-related toxicity.
Surgery was delayed more than 9 weeks after the end
of treatment in 4 patients in arm A, and 5 in arm B.
There were no differences in the surgical technique
performed nor in the frequency of anal sphincter preser-
vation. Nineteen patients (43%) and 18 (39%) patients in
arm A and B experienced at least one postoperative
complication, respectively. 10 patients (7 in arm A
(16.3%) and 3 in arm B (6.5%)) required repeat surgery,
due to suture failures (Table 1). There were no
perioperative deaths. There were no differences for
hospitalization time among arms: 11 vs 10 days for arm
A and b respectively.
Eighty-three percent of the patients (34 patients in
arm A and 41 patients in arm B) received adjuvant
Table 3 Adjuvant treatment after surgery
A (BVZ + CAPE + RT) (N = 44) B (CAPE + RT) (N = 46) Total (N = 90)
Patients receiving adjuvant chemotherapy
No n (%) 10 (22.73) 5 (10.87) 15 (16.67)
Yes n (%) 34 (77.27) 41 (89.13) 75 (83.33)
Adjuvant schedule
capecitabine n (%) 18 (40.9) 21 (45.65) 39 (43.33)
XELOX n (%) 10 (22.73) 15 (32.61) 25 (27.78
FOLFOX n (%) 6 (13.64) 8 (17.39) 14 (15.56)
Oxaliplatin + Raltitrexed n (%) 1 (2.27) 1 (2.17 2 (2.22)
5-Fu n (%) – 2 (4.34) 2 (2.22)
Disease-Free Survival
44 40 37 33 28 28 0
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Fig. 1 Disease-free survival
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treatment, and 20% (8 patients in arm A and 10 in arm
B) received further systemic treatment for metastatic
disease.
Response to treatment
Pathological complete response was achieved in 15.9%
(95% CI 7–31%) and 10.9% (95% CI 4–24%) in arms A
and B, respectively. Although there were no differences
in histologic tumoral regression, a statistic trend was
found in primary tumour pathological downstaging
(Table 2).
Treatment after surgery
Thirty-four patients in arm A and 41 in arm B received
adjuvant treatment. Seventeen cases from arm A
received combination with oxaliplatin compared with 24
in arm B (Table 3).
Disease-free survival (DFS), distant-relapse free survival
(DRFS) and overall survival (OS)
DFS at 3 years in arm A (Fig. 1) was of 75% (CI 95%
59.42, 85.30); and 71.7% (CI95% 56.3, 82.50) in arm B.
At 5 years the DFS probability was of 68.18 (CI95%
52.27, 79.76) and 69.57% (CI95% 54.09, 80.71) for arms
A and B, respectively. DRFS probability at 3 and 5 years
was of 81.05% (65.65, 90.04) and 76.2% (60.27, 86.43) for
arm A, and 80.43% (65.77, 89.30) and 78.26% (63.36,
87.66) for Arm B (Table 4). Eleven patients (25%) of arm
A and 10 patients (21.7%) of arm B had a distant relapse,
(Fig. 2).
In an exploratory analysis, we observed a benefit
in DFS for those patients receiving BVZ that
achieved a T-downstaging (p = 0.012), as well as for
those receiving BVZ obtaining an N-downstaging
(p = 0.005). supplementary Figs. 1 and 2.
Seventeen patients died during the study. In arm A,
one patient died from advanced dementia, another from
Table 4 Distant relapse-free survival and progression free survival
Arm A (BVZ + CAPE + RT) Arm B (CAPE + RT)
Distant relapse-free survival 44 patients 46 patients
No of patients with event 11 (25.00%) 10 (21.74%)
No of censored patients 33 (75.00%) 36 (78.26%)
Percent Survival (%, 95 CI)
36 Time (months) 81.05 (65.65, 90.04) 80.43 (65.77, 89.30)
60 Time (months) 76.20 (60.27, 86.43) 78.26 (63.36, 87.66)
Kaplan-Meier model
P-value (Log-rank) 0.6923
Cox Model Hazard ratio (95% CI) Cox Model P-value
Arm A (BVZ + CAPE+RT) vs Arm B (CAPE+RT) 1.1887 (0.5047, 2.8000) 0.6924
Disease free survival
No of patients with event 15 (34.09%) 15 (32.61%)
Earliest contributing event:
Distant metastases 11 10
Second tumor 1 4
Death 3 1
No of censored patients 29 (65.91%) 31 (67.39%)
Lab
Median (95% CI) NA (62.76, NA) NA (64.13, NA)
25th–75th percentile 34.67 - NA 19.22 - NA
Percent Survival (%, 95 CI)
36months 75.00 (59.42, 85.30) 71.74 (56.36, 82.50)
60 months 68.18 (52.27, 79.76) 69.57 (54.09, 80.71)
Kaplan-Meier model
P-value (Log-rank) 0.9820
Cox Model Hazard ratio (95% CI) Cox Model P-value
Arm A (BVZ + CAPE+RT) vs Arm B (CAPE+RT) 1.0083 (0.4927, 2.0635) 0.9820
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complications of chronic obstructive pulmonary disease,
and 8 from disease progression. In arm B, 2 (38.6%)
patients died from unknown causes, 1 (14.3%) form
respiratory insufficiency, and 4 (57.4%) from disease
progression.
OS probability at 3 and 5 years was of 88.6% (CI 95%
74.83, 95.11) and 81.82 (CI95% 66.92, 90.46) for arm A,
and 95.65% (CI95% 83.71, 98.89) and 86.96 (CI95%
73.25, 93.92) for Arm B (Table 5). There were no OS
statistically significant differences among both treatment
arms (p = 0.33 Fig. 3).
Discussion
At present, LARC treatment has reached an elevated
percentage of local control with optimization of surgery
and neoadjuvant radiotherapy or chemoradiotherapy; the
current efforts are aimed at improving quality of life in
low-risk cases, and both increasing local control and
reducing distant metastases that are the leading cause of
neoplastic death in these patients [14].
In the last decade, most drugs tested concomitantly
with radiotherapy plus fluoropyrimidines in the pre-
operative setting have not succeeded to become new
treatment standards despite having previously shown
efficacy in the metastatic colorectal cancer setting. These
included oxaliplatin [15], irinotecan [16] and monoclonal
antibodies (MoAb) such as BVZ and Cetuximab [17].
The most promising exploratory combinations involved
oxaliplatin, that has been intensively studied in phase II
trials, with increased ypCR rate up to 21–37% [18, 19]
but no benefit in long term survival outcomes [20–24].
Due to the discouraging results of irinotecan in
the adjuvant colon cancer setting, this drug has not
been extensively studied as neoadjuvant treatment.
The ypCR rate communicated for Wang et al is in
the rage of those reported with oxaliplatin combina-
tions, although long term results have not been
reported [16].
The main objective of our study, ypCR (T and N), did
not show differences between treatment arms and it is
in the range of other studies (8–27%) [25–27], and
although we found an statistical trend to yPT downsta-
ging with capecitabine plus bevacizumab this was an
unplanned exploratory finding. This is in line with other
phases I and II trials of BVZ in combination with RT
and fluoropyrimidines alone (5-Fluorouracil [28] or
capecitabine [29]) or in combination with oxaliplatin
[18, 30–33] with response rates not better than with
chemotherapy alone (13–18%). Now we report the
results of long term DFS, DRFS, and OS, where we have
found no significant differences between treatment arms.
Interestingly 5-year DFS and OS results observed in our
study were somewhat inferior to others, which probably
relates to the randomized design and less restricted
selection criteria in our study. Toxicities observed in this
study were not different between arms; nevertheless,
more patients required surgery due to suture failures.
This might be related to BVZ despite the long time
elapsed between bevacizumab’s last dose and surgery.
Distant Metastases-Free Survival
44 40 37 34 29 29 0
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P= 0.6923Log-Rank
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Fig. 2 Distant relapse-free survival
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Some differences in the number of patients that re-
ceived postoperative chemotherapy and regimens used
were observed. Oxaliplatin was used in 41 patients
based on the results of adjuvant colon cancer clinical
trials [34, 35]. This drug has been studied in rectal
cancer in association with 5FU in several randomized
trials in rectal cancer showing no improvement in
survival [36–38] except for the ADORE trial in which
patients were randomized after surgery [39]. In this
study, the addition of OXL to adjuvant 5FU in
patients with positive lymph nodes after surgery im-
proved OS. However, the role of adjuvant chemother-
apy for patients with rectal cancer remains
controversial, and two Pooled analyses have shown
conflicting results [40, 41]. Furthermore, recommen-
dations of complementary treatment of rectal cancer
patients are mostly based on the results of old trials
(before pre-operative treatment was standard) [2, 42,
43]. We therefore assume that differences in the adju-
vant treatment have not affected substantially the
Table 5 Overall survival
Arm A (BVZ + CAPE + RT) Arm B (CAPE + RT)
Summary of events
No of patients 44 46
No of patients with event 10 (22.73%) 7 (15.22%)
No of censored patients 34 (77.27%) 39 (84.78%)
Lab
Median (95% CI) NA (NA, NA) NA (NA, NA)
25th–75th percentile NA - NA NA - NA
Percent Survival (%, 95 CI)
36months 88.64 (74.83, 95.11) 95.65 (83.71, 98.89)
60 months 81.82 (66.92, 90.46) 86.96 (73.25, 93.92)
Kaplan-Meier model
P-value (Log-rank) 0.3350
Cox Model Hazard ratio (95% CI) Cox Model P-value
Arm A (BVZ + CAPE+RT) vs Arm B (CAPE+RT) 1.6013 (0.6091, 4.2097) 0.3397
Overall survival
44 41 41 39 37 33 0
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Fig. 3 Overall survival
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long-term results of our study. OS survival and DFS
results from our study are consistent with other ran-
domized studies recently reported [19, 20, 32, 38, 44].
Conclusion
No differences in OS, DFS, or DRFS were obtained with
the inclusion of bevacizumab in the preoperative setting
of rectal cancer. These results are in line with those of
the main endpoint of the study and other reports that
have shown that the addition of bevacizumab does not
improve yPCR. At this time treatment with fluoropyri-
midines plus radiotherapy should continue to be consid-
ered the standard neoadjuvant treatment in rectal
cancer.
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